FDA Approves PhotoMedex Laser System for Dermatitis

RADNOR, Pa., Aug. 15 -- PhotoMedex Inc. has received US Food and Drug Administration (FDA) clearance to market the XTRAC laser system to treat atopic dermatitis. Atopic dermatitis, or eczema, is a chronic inflammation of the skin that can afflict persons of any age, but is considered to be the most common skin disease in children under the age of 11.
Jeff O'Donnell, President and CEO, commented, "We are very pleased to have received approval from the FDA so quickly. With 15 million Americans suffering from the disease, the ability to now treat eczema is another significant opportunity to expand the treatment platform for our XTRAC laser."